Metabolic Solutions Development Company Reports Positive Top-Line Results From Phase 2a Study of Its Second Compound to Treat Type 2 Diabetes

Bio-Medicine.Org

KALAMAZOO, Mich., Sept. 8, 2011 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) confirmed today the potential of MSDC-0602 to achieve significant glucose control in type 2 diabetes patients and increase insulin sensitivity based on preliminary analysis from its Phase 2a trial of MSDC-0602, a novel insulin sensitizer.

Importantly, given the blood glucose (HbA1c) lowering shown in this short study, these data support the company's expectation of a ≥1.5 percent reduction in HbA1c potentially without the undesirable weight gain and other PPAR-related side-effects(1). According to the Diabetes Control and Complications Trial [1], as HbA1c is lowered, the risks of diabetic complications such as eye, nerve and heart disease is significantly reduced.

"This proof-of-concept trial affirmed the potential of this novel insulin sensitizer to lower blood glucose and increase insulin sensitivity without the side-effects found with currently marketed products," said Jerry Colca, Ph.D., president and Chief Scientific Officer of MSDC. "The data are encouraging and we are proceeding to design a Phase 2b study of longer duration."

The safety, tolerability and efficacy of MSDC-0602 were evaluated in a 28-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose study in 129 patients with type 2 diabetes. Patients were randomized to MSDC-0602, 45 mg of pioglitazone or placebo. No safety concerns were uncovered for any treatments and all treatments were well tolerated. This study follows the completion of two Phase 1 trials in which no safety concerns were observed. Additional safety and expanded efficacy data will be obtained from a Phase 2b study of MSDC-0602 that is targeted to begin in the first quarter of 2012.

MSDC-0602 is an insulin sensitizer that is selective for a molecular target connecting mitochondrial metabolism to cell functio
'/>"/>

SOURCE [2]

Source URL (retrieved on *12/29/2014 - 7:06am*):
http://www.mdtmag.com/news/2011/09/metabolic-solutions-development-company-

reports-positive-top-line-results-phase-2a-study-its-second-compound-treat-type-2-diabetes

Links:
[1] http://diabetes.niddk.nih.gov/dm/pubs/control
[2] http://www.bio-medicine.org/medicine-technology-1/Metabolic-Solutions-Development-Company-Reports-Positive-Top-Line-Results-From-Phase-2a-Study-of-Its-Second-Compound-to-Treat-Type-2-Diabetes-20109-1/